The genome-wide supported CACNA1C gene polymorphisms and the risk of schizophrenia: an update meta-analysis

Abstract Background: The CACNA1C gene was defined as the risk gene for schizophrenia in a large GWAS of European ancestory by Psychiatric Genomics Consortium. Previous meta-analyses have focused on the association between CACNA1C gene rs1006737 and schizophrenia. However, the present study focused on whether there was a racial difference in the effect of CACNA1C gene rs1006737 on schizophrenia. In addition, rs2007044 and rs4765905 were used to analyzed the risk of schizophrenia.Methods: The pooled analysis, subgroup analysis, sensitivity analysis and publication bias were conducted.Results: A total of 18 studies met the inclusion criteria, 14 for rs1006737 (15,213 cases and 19,412 controls), 3 for rs2007044 (6007 cases and 6,518 controls), and 2 for rs4765905 (2,435 cases and 2,639 controls). Rs2007044 and rs4765905 were also related to schizophrenia in the only conducted allele model. For rs1006737, the allele contrast model, dominant model, recessive model, codominance models, and complete overdominance model were performed, and the overall meta-analysis showed significant differences between rs1006737 and schizophrenia. However, race-based subgroup analysis of rs1006737 and found that the genotypes GG and GG+GA were only protective factors for schizophrenia in European populations, while the GA genotype of rs1006737 only reduced the risk of schizophrenia in Asian populations.Conclusions: Rs1006737, rs2007044 and rs4765905 of CACNA1C gene were associated with susceptibility to schizophrenia. However, the influence model of rs1006737 on schizophrenia in Asian and European populations have both similarities and differences.

Download Full-text

The genome-wide supported CACNA1C gene polymorphisms and the risk of schizophrenia: an updated meta-analysis

10.21203/rs.2.24453/v2 ◽

2020 ◽

Author(s):

Yongping Liu ◽

Xue Wu ◽

Xi Xia ◽

Jun Yao ◽

Bao-jie Wang

Keyword(s):

Genome Wide Association Study ◽

Meta Analysis ◽

European Ancestry ◽

Bias Analysis ◽

Influence Model ◽

Asian Populations ◽

Model Study ◽

Genome Wide ◽

Meta Analyses ◽

European Populations

Abstract Background: The CACNA1C gene was defined as a risk gene for schizophrenia in a large genome-wide association study of European ancestry performed by the Psychiatric Genomics Consortium. Previous meta-analyses focused on the association between the CACNA1C gene rs1006737 and schizophrenia. The present study focused on whether there was a racial difference in the effect of the CACNA1C gene rs1006737 on schizophrenia. rs2007044 and rs4765905 were analyzed for their effect on the risk of schizophrenia. Methods: Pooled, subgroup, sensitivity, and publication bias analysis were conducted.Results: A total of 18 studies met the inclusion criteria, including fourteen rs1006737 studies (15,213 cases, 19,412 controls), three rs2007044 studies (6,007 cases, 6,518 controls), and two rs4765905 studies (2,435 cases, 2,639 controls). An allele model study also related rs2007044 and rs4765905 to schizophrenia. The overall meta-analysis for rs1006737, which included the allele contrast, dominant, recessive, codominance, and complete overdominance models, showed significant differences between rs1006737 and schizophrenia. However, the race-based subgroup analysis for rs1006737 found that the genotypes GG and GG + GA were only protective factors for schizophrenia in European populations. In contrast, the rs1006737 GA genotype only reduced the risk of schizophrenia in Asian populations. Conclusions: Rs1006737, rs2007044, and rs4765905 of the CACNA1C gene were associated with susceptibility to schizophrenia. However, the influence model for rs1006737 on schizophrenia in Asian and European populations demonstrated both similarities and differences between the two populations.

Download Full-text

The genome-wide supported CACNA1C gene polymorphisms and the risk of schizophrenia: an updated meta-analysis

10.21203/rs.2.24453/v3 ◽

2020 ◽

Author(s):

Yongping Liu ◽

Xue Wu ◽

Xi Xia ◽

Jun Yao ◽

Bao-jie Wang

Keyword(s):

Genome Wide Association Study ◽

Meta Analysis ◽

European Ancestry ◽

Bias Analysis ◽

Influence Model ◽

Model Study ◽

Genome Wide ◽

Meta Analyses ◽

Allele Contrast ◽

Allele Model

Abstract Background: The CACNA1C gene was defined as a risk gene for schizophrenia in a large genome-wide association study of European ancestry performed by the Psychiatric Genomics Consortium. Previous meta-analyses focused on the association between the CACNA1C gene rs1006737 and schizophrenia. The present study focused on whether there was an ancestral difference in the effect of the CACNA1C gene rs1006737 on schizophrenia. rs2007044 and rs4765905 were analyzed for their effect on the risk of schizophrenia. Methods: Pooled, subgroup, sensitivity, and publication bias analysis were conducted.Results: A total of 18 studies met the inclusion criteria, including fourteen rs1006737 studies (15,213 cases, 19,412 controls), three rs2007044 studies (6,007 cases, 6,518 controls), and two rs4765905 studies (2,435 cases, 2,639 controls). An allele model study also related rs2007044 and rs4765905 to schizophrenia. The overall meta-analysis for rs1006737, which included the allele contrast, dominant, recessive, codominance, and complete overdominance models, showed significant differences between rs1006737 and schizophrenia. However, the ancestral-based subgroup analysis for rs1006737 found that the genotypes GG and GG + GA were only protective factors for schizophrenia in Europeans. In contrast, the rs1006737 GA genotype only reduced the risk of schizophrenia in Asians. Conclusions: Rs1006737, rs2007044, and rs4765905 of the CACNA1C gene were associated with susceptibility to schizophrenia. However, the influence model for rs1006737 on schizophrenia in Asians and Europeans demonstrated both similarities and differences between the two ancestors.

Download Full-text

Association between dopamine receptor D2 genetic polymorphism TaqIA1 (C t) and susceptibility to alcohol dependence

10.1101/2020.04.15.20066498 ◽

2020 ◽

Author(s):

Amrita Choudhary ◽

Upendra Yadav ◽

Pradeep Kumar ◽

Vandana Rai

Keyword(s):

Alcohol Dependence ◽

Dopamine Receptor ◽

Meta Analysis ◽

Asian Population ◽

Recessive Model ◽

Case Control Studies ◽

Drd2 Gene ◽

Contrast Model ◽

The Relationship ◽

Allele Contrast

AbstractSeveral studies are published, which investigated dopamine receptor 2 (DRD2) gene TaqIA polymorphism as ris factor for alcohol dependence (AD) with positive and negative association. To derive a more precise estimation of the relationship, a meta-analysis of case-control studies that examined the association between DRD2 gene Taq1A polymorphism and alcohol dependence were performed. Eligible articles were identified through search of databases including PubMed, Science Direct, Springer link and Google Scholar. The association between the DRD2 TaqIA polymorphism and AD susceptibility was conducted using odds ratios (ORs) and 95 % confidence intervals (95 % CIs) as association measure.A total of 69 studies with 9,125 cases and 9,123 healthy controls were included in current meta-analysis. Results of present analysis showed significant association between DRD2 TaqIA polymorphism and AD risk using a five genetic modes (allele contrast model -OR=1.22, 95% CI=1.13-1.32, p<0.0001; homozygote model -OR= 1.35, 95%CI= 1.18-1.55; p= <0.0001; dominant model -OR= 1.29; 95%CI= 1.20-1.39; p<0.0001; recessive model-OR= 1.21; 95%CI= 1.08-1.36; p= 0.0006). There was no significant association found between In subgroup analysis, TaqIA polymorphism was not significantly associated with AD risk in Asian population under all genetic models, but in Caucasian population TaqIA polymorphism was significantly associated with AD risk.Overall, results support the hypothesis that DRD2 Taq1A polymorphism plays a role in alcohol dependence.

Download Full-text

Flunarizine as prophylaxis for episodic migraine: a systematic review with meta-analysis

Ból ◽

10.5604/01.3001.0013.4615 ◽

2019 ◽

Vol 20 (1) ◽

pp. 25-38

Author(s):

Anker Stubberud ◽

Nikolai Melseth Flaaen ◽

Douglas C. McCrory ◽

Sindre Andre Pedersen ◽

Mattias Linde

Keyword(s):

Confidence Interval ◽

Meta Analysis ◽

Episodic Migraine ◽

Pooled Analysis ◽

Risk Of Bias ◽

Current Guideline ◽

Data Synthesis ◽

Randomized Controlled ◽

The Mean ◽

Meta Analyses

Based on few clinical trials, flunarizine is considered a first-line prophylactic treatment for migraine in several guidelines. In this meta-analysis, we examined the pooled evidence for its effectiveness, tolerability, and safety. Prospective randomized controlled trials of flunarizine as a prophylaxis against migraine were identified from a systematic literature search, and risk of bias was assessed for all included studies. Reduction in mean attack frequency was estimated by calculating the mean difference (MD), and a series of secondary outcomes –including adverse events (AEs) – were also analyzed. The database search yielded 879 unique records. Twentyfive studies were included in data synthesis. We scored 31/175 risk of bias items as “high”, with attrition as the most frequent bias. A pooled analysis estimated that flunarizine reduces the headache frequency by 0.4 attacks per 4 weeks compared with placebo (5 trials, 249 participants: MD 20.44; 95% confidence interval 20.61 to 2 0.26). Analysis also revealed that the effectiveness of flunarizine prophylaxis is comparable with that of propranolol (7 trials, 1151 participants, MD 20.08; 95% confidence interval 20.34 to 0.18). Flunarizine also seems to be effective in children. The most frequent AEs were sedation and weight increase. Meta-analyses were robust and homogenous, although several of the included trials potentially suffered from high risk of bias. Unfortunately, reporting of AEs was inconsistent and limited. In conclusion, pooled analysis of data from partially outdated trials shows that 10- mg flunarizine per day is effective and well tolerated in treating episodic migraine – supporting current guideline recommendations.

Download Full-text

Abstract P260: Large-scale Meta-analysis of Diverse Ancestry Genome-wide Association Studies to Identify Pharmacogenomic Interactions of Sulfonylureas and ECG Phenotypes

Circulation ◽

10.1161/circ.133.suppl_1.p260 ◽

2016 ◽

Vol 133 (suppl_1) ◽

Author(s):

James S Floyd ◽

Colleen Sitlani ◽

Christy L Avery ◽

Eric A Whitsel ◽

Leslie Lange ◽

...

Keyword(s):

Repeated Measures ◽

Qt Interval ◽

Association Studies ◽

Meta Analysis ◽

Small Sample ◽

Genome Wide Association ◽

European Ancestry ◽

Genome Wide Association Studies ◽

Genome Wide ◽

Meta Analyses

Introduction: Sulfonylureas are a commonly-used class of diabetes medication that can prolong the QT-interval, which is a leading cause of drug withdrawals from the market given the possible risk of life-threatening arrhythmias. Previously, we conducted a meta-analysis of genome-wide association studies of sulfonylurea-genetic interactions on QT interval among 9 European-ancestry (EA) cohorts using cross-sectional data, with null results. To improve our power to identify novel drug-gene interactions, we have included repeated measures of medication use and QT interval and expanded our study to include several additional cohorts, including African-American (AA) and Hispanic-ancestry (HA) cohorts with a high prevalence of sulfonylurea use. To identify potentially differential effects on cardiac depolarization and repolarization, we have also added two phenotypes - the JT and QRS intervals, which together comprise the QT interval. Hypothesis: The use of repeated measures and expansion of our meta-analysis to include diverse ancestry populations will allow us to identify novel pharmacogenomic interactions for sulfonylureas on the ECG phenotypes QT, JT, and QRS. Methods: Cohorts with unrelated individuals used generalized estimating equations to estimate interactions; cohorts with related individuals used mixed effect models clustered on family. For each ECG phenotype (QT, JT, QRS), we conducted ancestry-specific (EA, AA, HA) inverse variance weighted meta-analyses using standard errors based on the t-distribution to correct for small sample inflation in the test statistic. Ancestry-specific summary estimates were combined using MANTRA, an analytic method that accounts for differences in local linkage disequilibrium between ethnic groups. Results: Our study included 65,997 participants from 21 cohorts, including 4,020 (6%) sulfonylurea users, a substantial increase from the 26,986 participants and 846 sulfonylureas users in the previous meta-analysis. Preliminary ancestry-specific meta-analyses have identified genome-wide significant associations (P < 5х10–8) for each ECG phenotype, and analyses with MANTRA are in progress. Conclusions: In the setting of the largest collection of pharmacogenomic studies to date, we used repeated measurements and leveraged diverse ancestry populations to identify new pharmacogenomic loci for ECG traits associated with cardiovascular risk.

Download Full-text

Outcome of tantalum rod insertion in the treatment of osteonecrosis of the femoral head with minimum follow-up of 1 year: a meta-analysis and systematic review

Journal of Hip Preservation Surgery ◽

10.1093/jhps/hnaa020 ◽

2020 ◽

Vol 7 (2) ◽

pp. 329-339

Author(s):

James Randolph Onggo ◽

Mithun Nambiar ◽

Jason Derry Onggo ◽

Guan Tay ◽

Parminder J Singh ◽

...

Keyword(s):

Femoral Head ◽

Subgroup Analysis ◽

Bone Grafting ◽

Meta Analysis ◽

Degenerative Joint Disease ◽

Joint Disease ◽

Safe Alternative ◽

Meta Analyses ◽

Marginal Risk

Abstract Osteonecrosis of the femoral head (ONFH) is a debilitating disease that can cause deformity and collapse of the femoral head, thus leading to the development of degenerative joint disease that can incapacitate the patient with pain and reduction in hip mobility. This study aims to determine the safety and efficacy of tantalum rod insertion in the treatment of ONFH with a minimum follow-up period of 1 year. A multi-database search was performed according to Preferred Reporting Items for Systematic reviews and Meta-Analyses guidelines. Data from studies assessing the clinical and radiological outcomes as well as complications of tantalum rod insertion in the treatment of ONFH with a minimum follow-up period of 1 year were extracted and analyzed. Ten studies were included in this meta-analysis, consisting of 550 hips. There was a statistically significant increase in HHS (MD = 30.35, 95% CI: 20.60–40.10, P < 0.001) at final follow-up versus pre-operative scores. The weighted pooled proportion (PP) of radiographic progression of ONFH was 0.221 (95% CI: 0.148–0.316), while that of progression into femoral head collapse was 0.102 (95% CI: 0.062–0.162). Conversion to total hip arthroplasty (THA) had a PP of 0.158 (95% CI: 0.107–0.227) with a mean weighted period of 32.4 months (95% CI: 24.9–39.9 months). Subgroup analysis of conversion to THA when tantalum rods were used in conjunction with bone grafting (PP = 0.150, 95% CI: 0.092–0.235) showed a marginal risk reduction than when compared with subgroup analysis of tantalum rods being used alone (PP = 0.154, 95% CI: 0.078–0.282). Tantalum rod is a safe alternative option to the current joint-preserving procedures available in the treatment of ONFH. However, more studies are needed to investigate and identify the most appropriate patients who would benefit most and the synergistic effect brought on by the use of complementary biological augmentation of bone grafting or stem cells with tantalum rods.

Download Full-text

Association between BRCA1 polymorphisms rs799917 and rs1799966 and breast cancer risk: a meta-analysis

Journal of International Medical Research ◽

10.1177/0300060519826819 ◽

2019 ◽

Vol 47 (4) ◽

pp. 1409-1416

Author(s):

Meiming Yang ◽

Xiaoli Du ◽

Feng Zhang ◽

Shifang Yuan

Keyword(s):

Breast Cancer ◽

Breast Cancer Risk ◽

Cancer Risk ◽

Confidence Intervals ◽

Subgroup Analysis ◽

Meta Analysis ◽

Recessive Model ◽

Dominant Model ◽

Odds Ratios

Background Several studies have reported correlations between BRCA1 polymorphisms rs799917 and rs1799966 with the risk of breast cancer (BC). However, this relationship remains controversial. Methods We conducted a meta-analysis of seven studies to assess the associations between BRCA1 rs799917 and rs1799966 and BC risk, with the aim of more accurately determining the potential correlation. Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated to evaluate the correlation of rs799917 and rs1799966 with BC risk. Results There was no overall correlation between BRCA1 rs799917 and BC risk (TT vs CC: OR = 0.87, 95% CI = 0.66–1.16; CT vs CC: OR = 1.02, 95% CI = 0.89–1.15; dominant model: OR = 0.99, 95% CI = 0.88–1.11; recessive model: OR = 0.87, 95% CI = 0.65–1.16). Subgroup analysis by ethnicity also revealed no significant correlation between rs799917 and BC risk in either Asians or Caucasians. There was also no significant association between BRCA1 rs1799966 and BC risk (GG vs AA: OR = 0.70, 95% CI = 0.33–1.47; AG vs AA: OR = 0.68, 95% CI = 0.35–1.30; dominant model: OR = 0.76, 95% CI = 0.49–1.06; recessive model: OR = 0.82, 95% CI = 0.49–1.36). Conclusion BRCA1polymorphisms rs799917 and rs1799966 were not significantly associated with BC risk in this meta-analysis.

Download Full-text

Abiraterone or docetaxel in men with metastatic castration-sensitive prostate cancer: A pooled analysis of castration resistance-free survival and toxicity.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.6_suppl.354 ◽

2018 ◽

Vol 36 (6_suppl) ◽

pp. 354-354 ◽

Cited By ~ 1

Author(s):

Joelle Helou ◽

Charles N Catton ◽

Glenn Bauman ◽

Rouhi Fazelzad ◽

Jacques Raphael

Keyword(s):

Prostate Cancer ◽

Meta Analysis ◽

Random Effect ◽

Initial Therapy ◽

Pooled Analysis ◽

Controlled Trials ◽

Cochrane Central Register ◽

Castration Resistance ◽

Free Survival ◽

Meta Analyses

354 Background: Recent meta-analyses suggested an improvement in overall survival (OS) with the addition of Abiraterone (A) vs Docetaxel (D) to androgen deprivation therapy (ADT) in the treatment of men with metastatic castration-sensitive prostate cancer. However, none have reported castration resistance-free survival (CFS) and toxicity data; two clinically relevant outcomes for physicians and patients. Methods: We conducted a systematic review and meta-analysis to assess CFS and toxicity of adding A or D to ADT in men with castration-sensitive prostate cancer. The electronic databases Ovid MEDLINE, Cochrane Central Register of Controlled Trials and EMBASE, were searched for randomized controlled trials. Pooled hazard ratios (HR) for CFS, and pooled risk ratios (RR) for grade 3 or higher toxicity were analyzed using the Mantel-Haenszel method and generic inverse variance. To account for between-studies heterogeneity, random-effect models were used to compute pooled estimates. Subgroup analyses compared patients on A and D in terms of CFS. Results: Five studies were included. The addition of A or D to ADT decreased the risk of development of castration-resistance by 53% (5 studies, 4,462 participants, HR = 0.47, 95% CI 0.33-0.67). In a subgroup analysis, the addition of A seemed to be better than D for the outcome CFS (5 studies, HR = 0.31, 95% CI 0.27-0.34 versus HR = 0.62, 95% CI 0.56-0.69, test for subgroup difference, p< 0.001). Different profiles of toxicity were seen with A and D. While A increased the risk of hypokalemia (3,107 participants, HR = 6.63, 95% CI 3.5-12.5) and cardiac toxicity (3,107 participants, HR = 2.4, 95% CI 1.7-3.3), D increased the risk of neutropenia (2,151 participants, HR = 13, 95% CI 8.9-18.8) and neuropathy (2,151 participants, HR = 2.25, 95% CI 1.18-4.3). Conclusions: The addition of A and D to ADT increases CFS in men with castration-sensitive prostate cancer, with a longer CFS noted for A compared to D. Considering CFS and OS, A may be preferred to D as initial therapy. Toxicity profiles differed between A and D. Quality of life and cost differences between A and D are other important factors and were not considered in this analysis.

Download Full-text

Altered central and blood glutathione in Alzheimer Disease and Mild Cognitive Impairment: a meta-analysis

10.21203/rs.3.rs-430047/v1 ◽

2021 ◽

Author(s):

Jinghan J Chen ◽

Mathura Thiyagarajah ◽

Jianmeng Song ◽

Clara Chen ◽

Nathan Herrmann ◽

...

Keyword(s):

Cognitive Impairment ◽

Mild Cognitive Impairment ◽

Alzheimer Disease ◽

Publication Bias ◽

Subgroup Analysis ◽

Meta Analysis ◽

Random Effects Models ◽

Mean Differences ◽

Meta Analyses

Abstract Background: Increasing evidence implicates oxidative stress (OS) in Alzheimer Disease (AD) and Mild Cognitive Impairment (MCI). Depletion of the brain antioxidant glutathione (GSH) may be important in OS-mediated neurodegeneration, though studies of post-mortem brain GSH changes in AD have been inconclusive. Recent in vivo measurements of brain and blood GSH may shed light on GSH changes earlier in the disease.Aim: To quantitatively review in vivo GSH in AD and MCI compared to healthy controls (HC) using meta-analyses. Method: Studies with in vivo brain or blood GSH levels in MCI or AD with a HC group were identified using Medline, PsychInfo, and Embase (1947-June 2020). Standardized mean differences (SMD) and 95% confidence intervals (CI) were calculated for outcomes using random effects models. Outcome measures included brain GSH (Meshcher-Garwood Point Resolved Spectroscopy (MEGA-PRESS) versus non-MEGA-PRESS), and blood GSH (intracellular versus extracellular) in AD and MCI. The Q statistic and Egger’s test were used to assess heterogeneity and risk of publication bias, respectively. Results: For brain GSH, 4 AD (AD=135, HC=223) and 4 MCI (MCI=213, HC=211) studies were included. For blood GSH, 26 AD (AD=1203, HC=1135) and 7 MCI (MCI=434, HC=408) studies were included. Brain GSH overall did not differ in AD or MCI compared to HC; however, the subgroup of studies using MEGA-PRESS reported lower brain GSH in AD (SMD [95%CI] -1.45 [-1.83, -1.06], p<0.001) and MCI (-1.15 [-1.71, -0.59], z=4.0, p<0.001). AD had lower intracellular and extracellular blood GSH overall (-1.10 [-1.58, -0.62], z=4.46, p<0.001). In a subgroup analysis, intracellular GSH was lower in MCI (-0.66 [-1.11, -0.21], p=0.025). Heterogeneity was observed throughout (I2 >85%) and not fully accounted by subgroup analysis. Egger’s test indicated risk of publication bias.Conclusion: Blood intracellular GSH decrease is seen in MCI, while both intra- and extracellular decreases were seen in AD. Brain GSH is decreased in AD and MCI in subgroup analysis. Potential bias and heterogeneity suggest the need for measurement standardization and additional studies to explore sources of heterogeneity.

Download Full-text

Prevalence difference of Helicobacter pylori infection between Tibetan and Han ethnics: A meta-analysis on epidemiologic studies

10.21203/rs.2.14220/v1 ◽

2019 ◽

Author(s):

Dan Bai ◽

Kai Liu ◽

An-Mo Wang ◽

Si-Yu Duan ◽

Wei-Han Zhang ◽

...

Keyword(s):

Helicobacter Pylori ◽

Subgroup Analysis ◽

Meta Analysis ◽

Gastrointestinal Symptoms ◽

Northwest China ◽

Epidemiologic Studies ◽

Sensitivity Analyses ◽

Human Gastric Cancer ◽

Northwestern Region ◽

Meta Analyses

Abstract Background Helicobacter pylori (Hp) appears worldwide prevalent as a primary carcinogenic pathogen of human gastric cancer. China is a multi-ethnic country, and the prevalence of Hp infection may be diverse among ethnics. This meta-analysis was conducted to compare the prevalence of Hp infection between Tibetan and Han ethnics.Methods The databases, PubMed, Web of Science, Blackwell Journals, CNKI, and Wanfang were searched. Those studies which reported the prevalence of Hp infection between Tibetans and Hans in China were eligible. There were no limitation to Hp detection method, publication language, and observation period. RevMan 5.3 and Stata 12.0 softwares were used for heterogeneity tests and meta-analyses. Meanwhile, subgroup analysis, sensitivity analysis and publication bias evaluation were performed where applicable.Results Totally, 11 studies with 3,826 Tibetans and 19,787 Hans were analyzed. The pooled prevalence of Hp infection were 62.2% and 55.3% among Tibetans and Hans, respectively. Tibetans had higher risk of Hp infection than Hans (OR=1.38, 95% CI 1.05-1.80). In subgroup analysis, those Tibetans with upper gastrointestinal symptoms (OR=1.51, 95% CI 1.06-2.16), inhabiting in Tibet (OR=1.51, 95% CI 1.22-1.87), or in Northwestern region (OR=1.15, 95% CI 1.00-1.31) had significantly higher risk of Hp infection. Additionally, in recent ten years, Hans appeared a decreased risk of Hp infection (OR=1.81, 95% CI 1.42-2.30). Heterogeneity was common, while sensitivity analyses showed partially inconsistent results against main findings.Conclusions This study demonstrated the higher prevalence of Hp infection in Tibetans compared with Hans, especially in recent years, or in the Tibet and the northwest China, as well as symptomatic Tibetans. It suggests tailored strategy and robustness need further consider for Hp screening and eradication among Tibetans.Trial registration: The present systematic review and meta-analysis was registered in the PROSPERO International Prospective Register of Systematic Reviews supported by the National Institute for Health Research of the National Health Service (NHS), UK (registration number: CRD42019121192).

Download Full-text